Return to Today's science sparks archives

2019-01-02

Fig. 1 Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive to BCL-2 inhibitor.

Fig. 1 Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive to BCL-2 inhibitor.
  • Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, Nanjangud G, Seshan VE, Wang S, Wendel HG, Younes A

  • Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12034-12039.
Open Access button

2019-01-03

Fig. 1 a) Dicentric chromosomes are formed by the fusion of dysfunctional telomeres during telomere crisis.

Fig. 1 a) Dicentric chromosomes are formed by the fusion of dysfunctional telomeres during telomere crisis.
  • von Morgen P, Maciejowski J

  • Genome Med. 2018 Nov 27;10(1):89.
Open Access button

2019-01-04

Fig. 2 (A) Working group consensus on preferred end points by biologic subtype and line of therapy. (B) Hypothetical scenarios for expected postprogression survival (PPS) and choice of preferred end point.

Fig. 2 (A) Working group consensus on preferred end points by biologic subtype and line of therapy. (B) Hypothetical scenarios for expected postprogression survival (PPS) and choice of preferred end point.
  • Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA

  • J Clin Oncol. 2018 Sep 13:JCO1800242.

2019-01-07

Fig. 2 FAT1 loss and clinical resistance.

Fig. 2 FAT1 loss and clinical resistance.
  • Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S

  • Cancer Cell. 2018 Dec 10;34(6):893-905.e8.

2019-01-08

Fig. 1 Tyrosine kinase inhibitors and antibodies or antibody–drug conjugates in clinical use or under clinical investigation to target EGFR, HER2, and HER3 in EGFR-mutant lung cancers.

Fig. 1 Tyrosine kinase inhibitors and antibodies or antibody–drug conjugates in clinical use or under clinical investigation to target EGFR, HER2, and HER3 in EGFR-mutant lung cancers.
  • Fan PD, Yu HA

  • Clin Cancer Res. 2018 Nov 15;24(22):5499-5501.

2019-01-09

Fig. 1 Reliability of somatic SNVs and INDELs detected by WES and high-depth amplicon sequencing validation of variants.

Fig. 1 Reliability of somatic SNVs and INDELs detected by WES and high-depth amplicon sequencing validation of variants.
  • Shi W, Ng CKY, Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Gerstein MB, Chagpar AB, Weigelt B, Pusztai L, Reis-Filho JS, Hatzis C

  • Cell Rep. 2018 Nov 6;25(6):1446-1457.
Open Access button

2019-01-10

Fig. 1 Chimeric Antigen Receptor (CAR) design across generations.

Fig. 1 Chimeric Antigen Receptor (CAR) design across generations.
  • Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR

  • J Immunother Cancer. 2018 Dec 4;6(1):137.
Open Access button

2019-01-11

Fig. 1 Coronal image from a whole body CT demonstrating a color-coded map of voxels with mean HU values within the range −29 and +150 (colored green on this image).

Fig. 1 Coronal image from a whole body CT demonstrating a color-coded map of voxels with mean HU values within the range −29 and +150 (colored green on this image).
  • Halpenny DF, Goncalves M, Schwitzer E, Golia Pernicka J, Jackson J, Gandelman S, Moskowitz CS, Postow M, Mourtzakis M, Caan B, Jones LW, Plodkowski AJ

  • Br J Radiol. 2018 Dec;91(1092):20180451.

2019-01-14

Fig. 3 Schistosome eggs involving the bladder wall.

Fig. 3 Schistosome eggs involving the bladder wall.
  • Park S, Reuter VE, Hansel DE

  • Histopathology. 2019 Jan;74(1):97-111.

2019-01-15

Fig. 1  Colonoscopy quality reporting by method. ADR indicates adenoma detection rate; NLP, natural language processing.

Fig. 1 Colonoscopy quality reporting by method. ADR indicates adenoma detection rate; NLP, natural language processing.
  • Lee JK, Jensen CD, Levin TR, Zauber AG, Doubeni CA, Zhao WK, Corley DA

  • J Clin Gastroenterol. 2019 Jan;53(1):e25-e30.

2019-01-16

Fig. 2 Molecular structure of methyl spiro-2,6-dioxopyrazine UVM147 based on X-ray crystallographic analysis.

Fig. 2 Molecular structure of methyl spiro-2,6-dioxopyrazine UVM147 based on X-ray crystallographic analysis.
  • Uprety R, Váradi A, Allaoa A, Redel-Traub GN, Palmer TC, Feinberg EN, Ferris AC, Pande VS, Pasternak GW, Majumdar S

  • Eur J Med Chem. 2018 Dec 22;164:241-251.

2019-01-17

Fig. 1 Representative subject 19 FDG-PET/CT coronal maximum intensity projection (MIP) images before (left) and 30 days after (right) CTL019 CAR-T cell immunotherapy demonstrating interval complete.

Fig. 1 Representative subject 19 FDG-PET/CT coronal maximum intensity projection (MIP) images before (left) and 30 days after (right) CTL019 CAR-T cell immunotherapy demonstrating interval complete.
  • Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J

  • Cytotherapy. 2018 Dec;20(12):1415-1418.

2019-01-18

Fig. 2 Identified dose-volume histogram thresholds for the 5 gastrointestinal symptoms after external beam radiation therapy alone for which the quantitative synthesis was considered.

Fig. 2 Identified dose-volume histogram thresholds for the 5 gastrointestinal symptoms after external beam radiation therapy alone for which the quantitative synthesis was considered.
  • Olsson CE, Jackson A, Deasy JO, Thor M

  • Int J Radiat Oncol Biol Phys. 2018 Aug 17. pii: S0360-3016(18)33546-6.

2019-01-21

Fig. 4 Immunochemistry for glypican‐3 highlights yolk sac tumour in a mixed tumour with embryonal carcinoma.

Fig. 4 Immunochemistry for glypican‐3 highlights yolk sac tumour in a mixed tumour with embryonal carcinoma.
  • Berney DM, Comperat E, Feldman DR, Hamilton RJ, Idrees MT, Samaratunga H, Tickoo SK, Yilmaz A, Srigley JR

  • Histopathology. 2019 Jan;74(1):171-183.

2019-01-22

Blood Journal, American Society of Hematology

Blood Journal, American Society of Hematology
  • Sarraf Yazdy M, Mato AR, Cheson BD

  • Blood. 2019 Jan 10;133(2):121-129.

2019-01-23

Fig. 1 Circulation of common respiratory viruses in a large geographic area within the Northern Hemisphere.

Fig. 1 Circulation of common respiratory viruses in a large geographic area within the Northern Hemisphere.
  • Charlton CL, Babady E, Ginocchio CC, Hatchette TF, Jerris RC, Li Y, Loeffelholz M, McCarter YS, Miller MB, Novak-Weekley S, Schuetz AN, Tang YW, Widen R, Drews SJ

  • Clin Microbiol Rev. 2018 Dec 12;32(1). pii: e00042-18.

2019-01-24

Fig. 1 Oncogenic mutant allele imbalance in advanced cancers.

Fig. 1 Oncogenic mutant allele imbalance in advanced cancers.
  • Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, Berger MF, Taylor BS

  • Cancer Cell. 2018 Nov 12;34(5):852-862.e4.

2019-01-25

Fig. 1 The dietary supplement CHSA selectively promotes BRAF V600E-positive melanoma PDX tumor growth in the presence of PTEN.

Fig. 1 The dietary supplement CHSA selectively promotes BRAF V600E-positive melanoma PDX tumor growth in the presence of PTEN.
  • Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J

  • Mol Cell. 2018 Mar 15;69(6):923-937.e8.

2019-01-28

Fig. 1 Predicted Impact of Events Score–Revised score from logistic regression by Hospital Anxiety and Depression Scale score, adjusted for multiple respondents.

Fig. 1 Predicted Impact of Events Score–Revised score from logistic regression by Hospital Anxiety and Depression Scale score, adjusted for multiple respondents.
  • Wendlandt B, Ceppe A, Choudhury S, Nelson JE, Cox CE, Hanson LC, Danis M, Tulsky JA, Carson SS

  • Ann Am Thorac Soc. 2018 Dec;15(12):1451-1458.

2019-01-29

Fig. 2 Ablation devices commonly used.

Fig. 2 Ablation devices commonly used.
  • Cornelis FH, Solomon SB

  • J Nucl Med. 2018 Dec;59(12):1801-1808.

2019-01-30

Fig. 1 Immunotherapeutic targets in urothelial malignancies.

Fig. 1 Immunotherapeutic targets in urothelial malignancies.
  • Iyer G, Rosenberg JE

  • Ann Oncol. 2018 Dec 1;29(12):2302-2312.

2019-01-31

Fig. 1 Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor regression.

Fig. 1 Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor regression.
  • Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM

  • Ann Oncol. 2018 Aug 1;29(8):1853-1860.

2019-02-01

Fig. 1 Clinical Pattern of Acquired Resistance.

Fig. 1 Clinical Pattern of Acquired Resistance.
  • Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM

  • J Immunother Cancer. 2018 Nov 20;6(1):127.
Open Access button

2019-02-04

Fig. 1 Flow diagram of our general management strategies for patients with solid tumors with findings of clonal hematopoiesis (CH).

Fig. 1 Flow diagram of our general management strategies for patients with solid tumors with findings of clonal hematopoiesis (CH).
  • Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E

  • J Clin Oncol. 2019 Jan 1;37(1):7-11.

2019-02-05

Fig. 2 Types of individualized local therapy for infants treated on Children's Oncology Group ARST0331 (low-risk protocol) and ARST0531 (intermediate-risk protocol).

Fig. 2 Types of individualized local therapy for infants treated on Children's Oncology Group ARST0331 (low-risk protocol) and ARST0531 (intermediate-risk protocol).
  • Bradley JA, Kayton ML, Chi YY, Hawkins DS, Tian J, Breneman J, Wolden SL, Walterhouse D, Rodeberg DA, Donaldson SS

  • Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):19-27.

2019-02-06

Fig. 1 Progressive changes in neocortical interneuron output of dividing NKX2.1+ MGE/PoA RGPs.

Fig. 1 Progressive changes in neocortical interneuron output of dividing NKX2.1+ MGE/PoA RGPs.
  • Sultan KT, Liu WA, Li ZL, Shen Z, Li Z, Zhang XJ, Dean O, Ma J, Shi SH

  • Nat Commun. 2018 Nov 2;9(1):4595.
Open Access button

2019-02-07

Fig. 1 miR-155-mediated Ago binding occurs at distinct sites in four immune cell types.

Fig. 1 miR-155-mediated Ago binding occurs at distinct sites in four immune cell types.
  • Hsin JP, Lu Y, Loeb GB, Leslie CS, Rudensky AY

  • Nat Immunol. 2018 Oct;19(10):1137-1145.

2019-02-08

Fig. 1 Core components of integrative oncology for evidence-informed patient-centered care: (A) three main therapeutic categories, and (B) components of evidence-informed practice.

Fig. 1 Core components of integrative oncology for evidence-informed patient-centered care: (A) three main therapeutic categories, and (B) components of evidence-informed practice.
  • Latte-Naor S, Mao JJ

  • J Oncol Pract. 2019 Jan;15(1):7-14.

2019-02-11

Fig. 1 Evaluation of dermoscopic features on a formalin-fixed specimen (ex vivo dermoscopy) using a smartphone attached to a dermoscope.

Fig. 1 Evaluation of dermoscopic features on a formalin-fixed specimen (ex vivo dermoscopy) using a smartphone attached to a dermoscope.
  • Yélamos O, Braun RP, Liopyris K, Wolner ZJ, Kerl K, Gerami P, Marghoob AA

  • J Am Acad Dermatol. 2019 Feb;80(2):365-377.

2019-02-12

Fig. 1 Breast white adipose tissue inflammation by BMI category (n = 91).

Fig. 1 Breast white adipose tissue inflammation by BMI category (n = 91).
  • Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, Falcone DJ, Winston LA, Zhou XK, Hudis CA, Hershman DL, Dannenberg AJ, Iyengar NM

  • Cancer Prev Res (Phila). 2019 Jan;12(1):21-30.

2019-02-13

Fig. 1 Vascular structures and fibrosis of basal cell carcinoma on dermoscopy.

Fig. 1 Vascular structures and fibrosis of basal cell carcinoma on dermoscopy.
  • Cameron MC, Lee E, Hibler BP, Giordano CN, Barker CA, Mori S, Cordova M, Nehal KS, Rossi AM

  • J Am Acad Dermatol. 2019 Feb;80(2):321-339.

2019-02-14

Fig. 1 Cathepsin K-Cre labels periosteal mesenchymal cells.

Fig. 1 Cathepsin K-Cre labels periosteal mesenchymal cells.
  • Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, Li N, Liu Y, Yang YS, Eiseman M, Shim JH, Hameed M, Healey JH, Bostrom MP, Landau DA, Greenblatt MB

  • Nature. 2018 Oct;562(7725):133-139.

2019-02-18

Figure 1 WL12 binding interface on PD-L1 overlaps with PD-1 and PD-L1 therapeutics.

Figure 1 WL12 binding interface on PD-L1 overlaps with PD-1 and PD-L1 therapeutics.
  • Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S

  • J Clin Invest. 2019 Feb 1;129(2):616-630.
Open Access button

2019-02-19

Fig. 1 CRC test exposure trajectories and failures in people who died of CRC, KPNC and KPSC 2006–2012.

Fig. 1 CRC test exposure trajectories and failures in people who died of CRC, KPNC and KPSC 2006–2012.
  • Doubeni CA, Fedewa SA, Levin TR, Jensen CD, Saia C, Zebrowski AM, Quinn VP, Rendle KA, Zauber AG, Becerra-Culqui TA, Mehta SJ, Fletcher RH, Schottinger J, Corley DA

  • Gastroenterology. 2019 Jan;156(1):63-74.e6.

2019-02-20

Fig 6. Model of Hsp90 dependence and sensitivity to Hsp90 inhibitors.

Fig 6. Model of Hsp90 dependence and sensitivity to Hsp90 inhibitors.
  • Echeverria PC, Bhattacharya K, Joshi A, Wang T, Picard D

  • PLoS One. 2019 Feb 6;14(2):e0208287.
Open Access button

2019-02-21

Figure 4. SCOT-Macrophage-KO Mice Exhibit Normal Physiological Responses to HFD.

Figure 4. SCOT-Macrophage-KO Mice Exhibit Normal Physiological Responses to HFD.
  • Puchalska P, Martin SE, Huang X, Lengfeld JE, Daniel B, Graham MJ, Han X, Nagy L, Patti GJ, Crawford PA

  • Cell Metab. 2019 Feb 5;29(2):383-398.e7

2019-02-22

Fig. 2 Maximum change in tumour size at the RP2D, according to tumour type.

Fig. 2 Maximum change in tumour size at the RP2D, according to tumour type.
  • Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS

  • Br J Cancer. 2018 Dec;119(12):1471-1476.

2019-02-25

Acute lysolecithin lesions of the mouse corpus callosum are softer than healthy tissue.

Acute lysolecithin lesions of the mouse corpus callosum are softer than healthy tissue.
  • Urbanski MM, Brendel MB, Melendez-Vasquez CV

  • Sci Rep. 2019 Jan 30;9(1):999.
Open Access button

2019-02-26

Alderson phantom positioned underneath the beam-defining collimator of the 250 kVp x-ray machine at PXI.

Alderson phantom positioned underneath the beam-defining collimator of the 250 kVp x-ray machine at PXI.
  • Dilmanian FA, Krishnan S, McLaughlin WE, Lukaniec B, Baker JT, Ailawadi S, Hirsch KN, Cattell RF, Roy R, Helfer J, Kruger K, Spuhler K, He Y, Tailor R, Vassantachart A, Heaney DC, Zanzonico P, Gobbert MK, Graf JS, Nassimi JR, Fatemi NN, Schweitzer ME, Bangiyev L, Eley JG

  • Sci Rep. 2019 Feb 4;9(1):1198.
Open Access button

2019-02-27

Fig. 1 Structure of PARPi-FL, schematic diagram and characterization of PARPi-FL NE.

Fig. 1 Structure of PARPi-FL, schematic diagram and characterization of PARPi-FL NE.
  • Gonzales J, Kossatz S, Roberts S, Pirovano G, Brand C, Pérez-Medina C, Donabedian P, de la Cruz MJ, Mulder WJM, Reiner T

  • Bioconjug Chem. 2018 Nov 21;29(11):3776-3782.

2019-02-28

Schema for trials of extended adjuvant endocrine therapy. ABCSG, Austrian Breast Cancer Study Group.

Schema for trials of extended adjuvant endocrine therapy. ABCSG, Austrian Breast Cancer Study Group.
  • Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ

  • J Clin Oncol. 2019 Feb 10;37(5):423-438.

2019-03-01

Fig. 3. The thyroid gland is retracted anteriorly and medially, exposing the posterior surface of thyroid gland. This helps in the identification of the middle thyroid vein(s), which is (are) then ligated and divided.

Fig. 3. The thyroid gland is retracted anteriorly and medially, exposing the posterior surface of thyroid gland. This helps in the identification of the middle thyroid vein(s), which is (are) then ligated and divided.
  • Roman BR, Randolph GW, Kamani D

  • Endocrinol Metab Clin North Am. 2019 Mar;48(1):125-141.

2019-03-04

Fig. 2 Diagnosis-specific cumulative incidence of a first grade 3–5 chronic condition by diagnosis decade.

Fig. 2 Diagnosis-specific cumulative incidence of a first grade 3–5 chronic condition by diagnosis decade.
  • Gibson TM, Mostoufi-Moab S, Stratton KL, Leisenring WM, Barnea D, Chow EJ, Donaldson SS, Howell RM, Hudson MM, Mahajan A, Nathan PC, Ness KK, Sklar CA, Tonorezos ES, Weldon CB, Wells EM, Yasui Y, Armstrong GT, Robison LL, Oeffinger KC

  • Lancet Oncol. 2018 Dec;19(12):1590-1601.

2019-03-05

Effects of PGPC and p-CA on induction of apoptosis in U-2OS cells.

Effects of PGPC and p-CA on induction of apoptosis in U-2OS cells.
  • Nani, A, Belarbi, M, Murtaza, B, Benammar, C, Merghoub, T, Rialland, M, Akhtar Khan, N, Hichami, A

  • Journal of Functional Foods, 54, 422-432.

2019-03-06

Fig 3. Boom is rotated to face the pelvis for rectum dissection.

Fig 3. Boom is rotated to face the pelvis for rectum dissection.
  • Jimenez-Rodriguez RM, Quezada-Diaz F, Tchack M, Pappou E, Wei IH, Smith JJ, Nash GM, Guillem JG, Paty PB, Weiser MR, Garcia-Aguilar J

  • Surg Endosc. 2019 Mar;33(3):966-971.

2019-03-07

Fig. 1 BRAFL514V emerges upon RAF inhibitor response and resistance in a patient with pediatric glioma.

Fig. 1 BRAFL514V emerges upon RAF inhibitor response and resistance in a patient with pediatric glioma.
  • Wang J, Yao Z, Jonsson P, Allen AN, Qin ACR, Uddin S, Dunkel IJ, Petriccione M, Manova K, Haque S, Rosenblum MK, Pisapia DJ, Rosen N, Taylor BS, Pratilas CA

  • Cancer Discov. 2018 Sep;8(9):1130-1141.

2019-03-08

Fig. 1 Time to disease progression based on minimal residual disease (MRD)–negative complete remission (CR) status.

Fig. 1 Time to disease progression based on minimal residual disease (MRD)–negative complete remission (CR) status.
  • Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O

  • JAMA Oncol. 2018 Dec 1;4(12):1781-1783.

2019-03-11

Fig 7. Three-dimensional photographic comparison of a unilateral abdominoplasty scar before and 12 weeks after twice-daily application of SKN2017B on one side (A) and silicone cream on the other side (B) in this 45-year-old, African American woman. There is noticeable improvement in pigmentation, vascularity, pliability, and height of the side treated with SKN2017B (C). In contrast, the side treated with silicone cream shows a worsening in pigmentation and height of the scar (D).

Fig 7. Three-dimensional photographic comparison of a unilateral abdominoplasty scar before and 12 weeks after twice-daily application of SKN2017B on one side (A) and silicone cream on the other side (B) in this 45-year-old, African American woman. There is noticeable improvement in pigmentation, vascularity, pliability, and height of the side treated with SKN2017B (C). In contrast, the side treated with silicone cream shows a worsening in pigmentation and height of the scar (D).
  • Zoumalan CI, Tadayon SC, Roostaeian J, Rossi AM, Gabriel A

  • Aesthet Surg J. 2019 Feb 15;39(3):319-330.
Open Access button

2019-03-14

Fig 1. Vascular normalization potentiates the efficacy of oncolytic immunotherapy.

Fig 1. Vascular normalization potentiates the efficacy of oncolytic immunotherapy.
  • Bykov Y, Zamarin D

  • Clin Cancer Res. 2019 Mar 1;25(5):1446-1448.

2019-03-15

Fig 1. Immune checkpoint molecules at the T cell–tumor interface. A2aR, adenosine A2a receptor; B7RP1, B7-related protein 1; BTLA, B and T lymphocyte attenuator; GAL9, galectin 9; HVEM, herpesvirus entry mediator; ICOS, inducible T-cell costimulator; IL, interleukin; KIR, killer cell immunoglobulinlike receptor; LAG3, lymphocyte activation gene 3; PD1, programmed cell death protein 1; PDL, PD1 ligand; TGFβ, transforming growth factor-β; TIM3, T cell membrane protein 3.

Fig 1. Immune checkpoint molecules at the T cell–tumor interface. A2aR, adenosine A2a receptor; B7RP1, B7-related protein 1; BTLA, B and T lymphocyte attenuator; GAL9, galectin 9; HVEM, herpesvirus entry mediator; ICOS, inducible T-cell costimulator; IL, interleukin; KIR, killer cell immunoglobulinlike receptor; LAG3, lymphocyte activation gene 3; PD1, programmed cell death protein 1; PDL, PD1 ligand; TGFβ, transforming growth factor-β; TIM3, T cell membrane protein 3.
  • Ku GY

  • Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338.

2019-03-18

Fig 11. Immunostaining of cytologic specimens.

Fig 11. Immunostaining of cytologic specimens.
  • Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL

  • J Thorac Oncol. 2019 Mar;14(3):377-407.

2019-03-19

Fig. 1 Clonal hematopoiesis (CH)-derived mutations observed in solid tumors (CH-ST).

Fig. 1 Clonal hematopoiesis (CH)-derived mutations observed in solid tumors (CH-ST).
  • Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, Solit DB, Baselga J, Arcila ME, Ladanyi M, Zhang L, Levine RL, Berger MF, Zehir A

  • JAMA Oncol. 2018 Nov 1;4(11):1589-1593.

2019-03-20

Fig 1. Long-lived DSB hotspots occur primarily in EARs.

Fig 1. Long-lived DSB hotspots occur primarily in EARs.
  • Subramanian VV, Zhu X, Markowitz TE, Vale-Silva LA, San-Segundo PA, Hollingsworth NM, Keeney S, Hochwagen A

  • Nat Commun. 2019 Feb 27;10(1):970
Open Access button

2019-03-21

Fig. 1 Differentiation and functional characterization of trigeminal neurons derived from human iPSC under fully defined conditions.

Fig. 1 Differentiation and functional characterization of trigeminal neurons derived from human iPSC under fully defined conditions.
  • Zimmer B, Ewaleifoh O, Harschnitz O, Lee YS, Peneau C, McAlpine JL, Liu B, Tchieu J, Steinbeck JA, Lafaille F, Volpi S, Notarangelo LD, Casanova JL, Zhang SY, Smith GA, Studer L

  • Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8775-E8782.

2019-03-22

Fig. 1: Comparison of PathoMAN results against expertly curatedvariants.

Fig. 1: Comparison of PathoMAN results against expertly curatedvariants.
  • Ravichandran V, Shameer Z, Kemel Y, Walsh M, Cadoo K, Lipkin S, Mandelker D, Zhang L, Stadler Z, Robson M, Offit K, Vijai J

  • Genet Med. 2019 Feb 21.

2019-03-25

Figure 1. Hierarchical Clustering of the Human Kinome by Inhibition Phenotype Reveals a Group of Highly Promiscuous Kinases.

Figure 1. Hierarchical Clustering of the Human Kinome by Inhibition Phenotype Reveals a Group of Highly Promiscuous Kinases.
  • Hanson SM, Georghiou G, Thakur MK, Miller WT, Rest JS, Chodera JD, Seeliger MA

  • Cell Chem Biol. 2019 Mar 21;26(3):390-399.e5

2019-03-26

Fig. 1. Perineural invasion is a histologic finding.

Fig. 1. Perineural invasion is a histologic finding.
  • Bakst RL, Glastonbury CM, Parvathaneni U, Katabi N, Hu KS, Yom S

  • Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1109-1124.

2019-03-27

Figure 3. Mass Spectrometry of RBM39 Proteome Identifies an RBP Network Required in AML.

Figure 3. Mass Spectrometry of RBM39 Proteome Identifies an RBP Network Required in AML.
  • Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, Hockemeyer K, Ghebrechristos YE, Yoshimi A, Inoue D, Ki M, Cho H, Bitner L, Kloetgen A, Lin KT, Uehara T, Owa T, Tibes R, Krainer AR, Abdel-Wahab O, Aifantis I

  • Cancer Cell. 2019 Mar 18;35(3):369-384.e7.

2019-03-28

Fig. 1. Topo III colocalizes with the β subunit of the DNA Pol III HE at the replication fork

Fig. 1. Topo III colocalizes with the β subunit of the DNA Pol III HE at the replication fork
  • Lee CM, Wang G, Pertsinidis A, Marians KJ

  • J Bacteriol. 2019 Mar 13;201(7). pii: e00563-18.

2019-03-29

Fig. 1. Imaging of the 3 patients with marginal failures showing the extent of tumor at diagnosis, the radiation therapy fields, and the location of the marginal failure outside of the radiation therapy field.

Fig. 1. Imaging of the 3 patients with marginal failures showing the extent of tumor at diagnosis, the radiation therapy fields, and the location of the marginal failure outside of the radiation therapy field.
  • Casey DL, Kushner BH, Cheung NV, Modak S, Basu EM, Roberts SS, LaQuaglia MP, Wolden SL

  • Int J Radiat Oncol Biol Phys. 2019 Feb 11. pii: S0360-3016(19)30194-4.

2019-04-01

Fig. 1. Dense colonization of the intestine by K. pneumoniae preceded K. pneumoniae bacteremia. Changes in the gut microbiota of an allo-HCT patient who developed.

Fig. 1. Dense colonization of the intestine by K. pneumoniae preceded K. pneumoniae bacteremia. Changes in the gut microbiota of an allo-HCT patient who developed.
  • Jung HJ, Littmann ER, Seok R, Leiner IM, Taur Y, Peled J, van den Brink M, Ling L, Chen L, Kreiswirth BN, Goodman AL, Pamer EG

  • MBio. 2019 Mar 12;10(2). pii: e02663-18.